Form 4: Alan Grujic Reports Changes in Beneficial Ownership of Guided Therapeutics Inc.
SEC Form 4 Filing
Alan Grujic, a director of Guided Therapeutics Inc., reports transactions involving stock options and warrants.
Summary
- Alan Grujic, a director of Guided Therapeutics Inc., filed a Form 4 detailing changes in his beneficial ownership.
- The report includes the acquisition of 100,000 stock options at an exercise price of $0.12, with vesting starting on July 9, 2024, and continuing monthly until July 8, 2027.
- Grujic also acquired 25,000 warrants at an exercise price of $0.25 in conjunction with a $25,000 note payable issued by the company on July 31, 2024.
- Additionally, 800,000 warrants at an exercise price of $0.50 expired on September 2, 2024.
- Following these transactions, Grujic directly owns 100,000 stock options and 500,000 warrants.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a routine filing detailing transactions. The acquisition of options and warrants could be seen as mildly positive, but the expiration of warrants is a neutral to slightly negative event.
Positives
- The acquisition of stock options and warrants by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Negatives
- The expiration of 800,000 warrants may indicate a missed opportunity for the company if those warrants were not exercised.
Risks
- The vesting schedule of the stock options means that the director's incentives are aligned with the company's long-term performance.
- The value of the warrants and stock options is dependent on the future performance of the company's stock.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The information is used by investors to gauge the sentiment of company leadership.
Comparison to Industry Standards
- Comparing the exercise prices of the options and warrants to the current market price of GTHP stock would provide a better understanding of their potential value.
- Reviewing similar filings from comparable companies in the medical device industry would offer context on the typical compensation structures for directors.
Related Party Transactions
- The issuance of a $25,000 note payable to Mr. Grujic and the associated warrants are related-party transactions.
Stakeholder Impact
- The transactions could influence investor perception of the company.
- The vesting schedule of the stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/02/2022 | Original date of warrants to purchase 800,000 shares of Common Stock at $0.50 per share |
| 07/09/2024 | Date of stock option grant and initial vesting of one-fourth of the shares. |
| 07/31/2024 | Date the Company issued a $25,000 note payable to Mr. Grujic and issued warrants to purchase 25,000 shares of Common Stock. |
| 07/31/2024 | Date of warrant grant to purchase 25,000 shares of Common Stock. |
| 09/02/2024 | Expiration date of warrants to purchase 800,000 shares of Common Stock at $0.50 per share. |
| 10/09/2024 | Start date for monthly vesting of remaining stock options. |
| 07/08/2027 | Date the stock options are fully vested. |
| 07/30/2028 | Expiration date of warrants to purchase 25,000 shares of Common Stock. |
| 09/03/2024 | Date of Form 4 filing. |
Keywords
Form 4, beneficial ownership, Guided Therapeutics Inc, GTHP, stock options, warrants, Alan Grujic, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.